+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 60Years
FEMALE
ID06028672

Study of Toripalimab Combined With Actinomycin-D Versus Actinomycin-D Alone as First-Line Treatment for Gestational Trophoblastic Neoplasia With FIGO Score 5-6

Led by Peking Union Medical College Hospital · Updated on 2025-02-06

40

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether combining toripalimab with actinomycin-D as a first-line treatment can improve the complete remission rate for patients with gestational trophoblastic neoplasia GTN who have a FIGO score of 5-6. The study also looks at whether multi-drug chemotherapy as a second-line treatment can achieve similar cure rates in patients who do not respond to the first-line combination therapy. This trial is a multicenter, open-label, randomized controlled study focused on the efficacy and safety of these treatments. Participants will be randomly assigned to one of two groups the experimental group will receive toripalimab 200mg intravenously every two weeks combined with actinomycin-D 1.25mgm2, max 2mg, intravenously every two weeks, while the control group will receive actinomycin-D alone on the same schedule. Treatment continues until disease progression, unacceptable side effects, or withdrawal of consent, followed by three cycles of consolidation therapy after serum beta-hCG levels normalize. During the study, participants will undergo evaluations including serum beta-hCG monitoring, biomarker analysis, ovarian function tests, and quality of life assessments up to one year. Researchers will measure outcomes such as complete remission rate, objective response rate, progression-free survival, disease control, duration of response, overall survival, treatment safety, and patient quality of life. The total participation includes treatment and follow-up lasting up to one year with safety monitoring throughout.

CONDITIONS

Brief Title

Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here